Metformin for Weight Loss in Schizophrenia

Nathan Kline Institute for Psychiatric Research

Status: Terminated

Conditions: Schizophrenia; Obesity

Treatments: Drug: Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT01177709

091/C22

Details and patient eligibility

About

Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.

Full description

Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 2500 mg/day in an open label study of up to 3 months time. Changes in weight and glucose measures were recorded.

Enrollment: 12 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients will be 18-70 years of age;
• Currently hospitalized or an outpatient at MPC;
• BMI ≥ 35 or excessive recent weight gain ( > than 10 lb weight gain in the past 3 months);
• Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder.

Exclusion criteria

• Age below 18 or over 70;
• Patient is currently already treated with metformin.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Metformin

Experimental group

Treatment:

Drug: Metformin